JPMorgan raised the firm’s price target on HealthEquity (HQY) to $129 from $126 and keeps an Overweight rating on the shares following the Q3 report. The says artificial intelligence is helping the company’s margins.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY:
- HealthEquity’s Strategic Growth and Market Position Justify Buy Rating
- Healthequity’s Strong Performance and Growth Prospects Justify Buy Rating
- HealthEquity price target raised to $122 from $117 at Citizens JMP
- HealthEquity Inc. Reports Strong Q3 Financial Performance
- HealthEquity raises FY26 EPS view to $3.87-$3.95 from $3.74-$3.91